Search

Your search keyword '"Dragun D"' showing total 406 results
Start Over Author "Dragun D"
406 results on '"Dragun D"'

1. The XIIIth Banff Conference on Allograft Pathology: The Banff 2015 Heart Meeting Report: Improving Antibody-Mediated Rejection Diagnostics: Strengths, Unmet Needs, and Future Directions

Author

Bruneval, P, Angelini, A, Miller, D, Potena, L, Loupy, A, Zeevi, A, Reed, EF, Dragun, D, Reinsmoen, N, Smith, RN, West, L, Tebutt, S, Thum, T, Haas, M, Mengel, M, Revelo, P, Fedrigo, M, Van Huyen, JP Duong, and Berry, GJ

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Cardiovascular, Heart Disease, Transplantation, Organ Transplantation, Graft Rejection, Humans, Isoantibodies, Practice Guidelines as Topic, Research Report, Transplantation, Homologous, clinical research, practice, heart transplantation, cardiology, rejection, rejection: antibody-mediated, rejection: subclinical, translational research, science, clinical research/practice, heart transplantation/cardiology, translational research/science, Medical and Health Sciences, Surgery, Clinical sciences, Immunology
Abstract

The 13th Banff Conference on Allograft Pathology was held in Vancouver, British Columbia, Canada from October 5 to 10, 2015. The cardiac session was devoted to current diagnostic issues in heart transplantation with a focus on antibody-mediated rejection (AMR) and small vessel arteriopathy. Specific topics included the strengths and limitations of the current rejection grading system, the central role of microvascular injury in AMR and approaches to semiquantitative assessment of histopathologic and immunophenotypic indicators, the role of AMR in the development of cardiac allograft vasculopathy, the important role of serologic antibody detection in the management of transplant recipients, and the potential application of new molecular approaches to the elucidation of the pathophysiology of AMR and potential for improving the current diagnostic system. Herein we summarize the key points from the presentations, the comprehensive, open and wide-ranging multidisciplinary discussion that was generated, and considerations for future endeavors.

Published
2017

2. The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology

Author

Loupy, A, Haas, M, Solez, K, Racusen, L, Glotz, D, Seron, D, Nankivell, BJ, Colvin, RB, Afrouzian, M, Akalin, E, Alachkar, N, Bagnasco, S, Becker, JU, Cornell, L, Drachenberg, C, Dragun, D, de Kort, H, Gibson, IW, Kraus, ES, Lefaucheur, C, Legendre, C, Liapis, H, Muthukumar, T, Nickeleit, V, Orandi, B, Park, W, Rabant, M, Randhawa, P, Reed, EF, Roufosse, C, Seshan, SV, Sis, B, Singh, HK, Schinstock, C, Tambur, A, Zeevi, A, and Mengel, M

Subjects
Organ Transplantation, Clinical Research, Transplantation, Detection, screening and diagnosis, 4.1 Discovery and preclinical testing of markers and technologies, Renal and urogenital, Arteritis, Complement C4b, Graft Rejection, Humans, Isoantibodies, Kidney Transplantation, Peptide Fragments, Research Report, clinical research, practice, translational research, science, kidney transplantation, nephrology, pathology, histopathology, organ transplantation in general, rejection, rejection: antibody-mediated, rejection: subclinical, rejection: T cell mediated, clinical research/practice, kidney transplantation/nephrology, pathology/histopathology, translational research/science, Medical and Health Sciences, Surgery
Abstract

The XIII Banff meeting, held in conjunction the Canadian Society of Transplantation in Vancouver, Canada, reviewed the clinical impact of updates of C4d-negative antibody-mediated rejection (ABMR) from the 2013 meeting, reports from active Banff Working Groups, the relationships of donor-specific antibody tests (anti-HLA and non-HLA) with transplant histopathology, and questions of molecular transplant diagnostics. The use of transcriptome gene sets, their resultant diagnostic classifiers, or common key genes to supplement the diagnosis and classification of rejection requires further consensus agreement and validation in biopsies. Newly introduced concepts include the i-IFTA score, comprising inflammation within areas of fibrosis and atrophy and acceptance of transplant arteriolopathy within the descriptions of chronic active T cell-mediated rejection (TCMR) or chronic ABMR. The pattern of mixed TCMR and ABMR was increasingly recognized. This report also includes improved definitions of TCMR and ABMR in pancreas transplants with specification of vascular lesions and prospects for defining a vascularized composite allograft rejection classification. The goal of the Banff process is ongoing integration of advances in histologic, serologic, and molecular diagnostic techniques to produce a consensus-based reporting system that offers precise composite scores, accurate routine diagnostics, and applicability to next-generation clinical trials.

Published
2017

3. Distribution of sialoglycoconjugates – gangliosides and PSA-NCAM in the brain of two venomous snakes: Vipera ammodytes and Vipera berus bosniensis.

Author

Viljetić, B., Dragun, D., Labak, I., Bogdanović, T., Jelić, D., Heffer, M., Kovačić, M., and Blažetić, S.

Subjects
POISONOUS snakes, VIPERA ammodytes, VIPERA berus, IMMUNOHISTOCHEMISTRY, NEUROGENESIS
Abstract

Copyright of Veterinarska Stanica is the property of Croatian Veterinary Institute and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2024
Full Text
View/download PDF

21. The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell– and antibody-mediated rejection

Author

Loupy, A. (Alexandre), Haas, M. (Mark), Roufosse, C. (Candice), Naesens, L., Adam, B. (Benjamin), Afrouzian, M. (Marjan), Akalin, E. (Enver), Alachkar, N. (Nada), Bagnasco, S. (Serena), Becker, J.U. (Jan U.), Cornell, L.D. (Lynn D.), Clahsen-van Groningen, M.C. (Marian), Demetris, A.J. (Anthony J.), Dragun, D. (Duska), Duong van Huyen, J.-P. (Jean-Paul), Farris, A.B. (Alton), Fogo, A.B. (Agnes), Gibson, I.W. (Ian), Glotz, D. (Denis), Gueguen, J. (Juliette), Kikic, Z. (Zeljko), Kozakowski, N. (Nicolas), Kraus, E. (Edward), Lefaucheur, C. (Carmen), Liapis, H. (Helen), Mannon, R.B. (Roslyn), Montgomery, R.A. (Robert A.), Nankivell, B.J. (Brian J.), Nickeleit, V. (Volker), Nickerson, P. (Peter), Rabant, M. (Marion), Racusen, L. (Lorraine), Randhawa, P. (Parmjeet), Robin, B. (Blaise), Rosales, I.A. (Ivy A.), Sapir-Pichhadze, R. (Ruth), Schinstock, C.A. (Carrie A.), Seron, D. (Daniel), Singh, H.K. (Harsharan K.), Smith, R.N. (Rex N.), Stegall, M.D. (Mark D.), Zeevi, A. (Adriana), Solez, K. (Kim), Colvin, R.B. (Robert B.), Mengel, M. (Michael), Loupy, A. (Alexandre), Haas, M. (Mark), Roufosse, C. (Candice), Naesens, L., Adam, B. (Benjamin), Afrouzian, M. (Marjan), Akalin, E. (Enver), Alachkar, N. (Nada), Bagnasco, S. (Serena), Becker, J.U. (Jan U.), Cornell, L.D. (Lynn D.), Clahsen-van Groningen, M.C. (Marian), Demetris, A.J. (Anthony J.), Dragun, D. (Duska), Duong van Huyen, J.-P. (Jean-Paul), Farris, A.B. (Alton), Fogo, A.B. (Agnes), Gibson, I.W. (Ian), Glotz, D. (Denis), Gueguen, J. (Juliette), Kikic, Z. (Zeljko), Kozakowski, N. (Nicolas), Kraus, E. (Edward), Lefaucheur, C. (Carmen), Liapis, H. (Helen), Mannon, R.B. (Roslyn), Montgomery, R.A. (Robert A.), Nankivell, B.J. (Brian J.), Nickeleit, V. (Volker), Nickerson, P. (Peter), Rabant, M. (Marion), Racusen, L. (Lorraine), Randhawa, P. (Parmjeet), Robin, B. (Blaise), Rosales, I.A. (Ivy A.), Sapir-Pichhadze, R. (Ruth), Schinstock, C.A. (Carrie A.), Seron, D. (Daniel), Singh, H.K. (Harsharan K.), Smith, R.N. (Rex N.), Stegall, M.D. (Mark D.), Zeevi, A. (Adriana), Solez, K. (Kim), Colvin, R.B. (Robert B.), and Mengel, M. (Michael)

Abstract

The XV. Banff conference for allograft pathology was held in conjunction with the annual meeting of the American Society for Histocompatibility and Immunogenetics in Pittsburgh, PA (USA) and focused on refining recent updates to the classification, advances from the Banff working groups, and standardization of molecular diagnostics. This report on kidney transplant pathology details clarifications and refinements to the criteria for chronic active (CA) T cell–mediated rejection (TCMR), borderline, and antibody-mediated rejection (ABMR). The main focus of kidney sessions was on how to address biopsies meeting criteria for CA TCMR plus borderline or acute TCMR. Recent studies on the clinical impact of borderline infiltrates were also presented to clarify whether the threshold for interstitial inflammation in diagnosis of borderline should be i0 or i1. Sessions on ABMR focused on biopsies showing microvascular inflammation in the absence of C4d staining or detectable donor-specific antibodies; the potential value of molecular diagnostics in such cases and recommendations for use of the latter in the setting of solid organ transplantation are presented in the accompanying meeting report. Finally, several speakers discussed the capabilities of artificial intelligence and the potential for use of machine learning algorithms in diagnosis and personalized therapeutics in solid organ transplantation.

Published
2020
Full Text
View/download PDF

22. The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell– and antibody-mediated rejection

Author

Loupy, A, de Haas, M, Roufosse, C, Naesens, M, Adam, B, Afrouzian, M, Akalin, E, Alachkar, N, Bagnasco, S, Becker, JU, Cornell, LD, Groningen, Marian, Demetris, AJ, Dragun, D, Duong van Huyen, JP, Farris, AB, Fogo, AB, Gibson, IW, Glotz, D, Gueguen, J, Kikic, Z, Kozakowski, N, Kraus, E, Lefaucheur, C, Liapis, H, Mannon, RB, Montgomery, RA, Nankivell, BJ, Nickeleit, V, Nickerson, P, Rabant, M, Racusen, L, Randhawa, P, Robin, B, Rosales, IA, Sapir-Pichhadze, R, Schinstock, CA, Seron, D, Singh, HK, Smith, RN, Stegall, MD, Zeevi, A, Solez, K, Colvin, RB, Mengel, M, Loupy, A, de Haas, M, Roufosse, C, Naesens, M, Adam, B, Afrouzian, M, Akalin, E, Alachkar, N, Bagnasco, S, Becker, JU, Cornell, LD, Groningen, Marian, Demetris, AJ, Dragun, D, Duong van Huyen, JP, Farris, AB, Fogo, AB, Gibson, IW, Glotz, D, Gueguen, J, Kikic, Z, Kozakowski, N, Kraus, E, Lefaucheur, C, Liapis, H, Mannon, RB, Montgomery, RA, Nankivell, BJ, Nickeleit, V, Nickerson, P, Rabant, M, Racusen, L, Randhawa, P, Robin, B, Rosales, IA, Sapir-Pichhadze, R, Schinstock, CA, Seron, D, Singh, HK, Smith, RN, Stegall, MD, Zeevi, A, Solez, K, Colvin, RB, and Mengel, M

Published
2020

38. Role of antibodies against PAR-1 and PAR-2 in cancer in the kidney transplant recipients

Author

Catar, R., Carroll, R., Chen, L., Li, Q., Schramm, I., Simon, M., Wischnewski, O., Kusch, A., Philippe, A., and Dragun, D.

Abstract

Background: Activated angiogenesis and impaired host immune response contribute to cancer in renal transplant recipients. Induction of VEGF is crucial for neoangiogenesis in tumors. Functional autoantibodies targeting GPCRs are able to induce endothelial dysfunction. We hypothesized that autoimmune GPCR targeting process may disturb VEGF induced angiogenesis. We identified in an in vitro model PAR-1 as novel activating autoantibody target and assessed the presence of this naturally occurring blocking antibody in 20 Kidney Transplant Recipients (KTR) with and 29 KTR without metastatic cancer. In further in vitro studies, we determined the influence of IgG derived from KTR on PAR-2-dependent G-protein activation Methods/Materials: Human endothelial cells were stimulated with IgG isolated from sera of kidney transplant recipients (KTR-IgG). Transcriptional regulation of VEGF was studied by promoter deletion assay. Transcription factor activation and binding was assessed by qRT-PCR, western blot, EMSA and cFOS knockdown. VEGF secretion was determined by ELISA. Tube formation on matrigel served to study endothelial neoangiogenic response. G-protein activation was measured by reporter assay. All 49 patients enrolled had sera for assessment of PAR antibodies (PAR-Ab) via ELISA in 2016 and at the time of transplantation. Results: Treatment with KTR-IgG reduced ERK1/2-dependent VEGF secretion and tube formation. VEGF secretion and endothelial tube formation could be restored by pretreatment with specific PAR-1 inhibitor. KTR-IgG contributed to deregulated neoangiogenesis via reduced VEGF promoter activity and increased cFos protein expression via its binding to the VEGF promoter. Mutation of extracellular loops of PAR2 receptor increased PAR2-Ab dependent Gq11 Signalling. Levels of PAR1-Ab were statistically significantly lower pre transplant and at diagnosis in those KTR who subsequently developed cancer compared to controls without cancer. Conclusion: We identified the PAR-1 receptor as a new target for functional antibodies in the context of kidney transplantation and tumor angiogenesis. PAR-1 regulated angiogenesis could offer new possibilities for treatment of kidney transplants to obviate tumor angiogenesis., Advances in RAB Research, Vol 1 No 1 (2018)

Published
2018
Full Text
View/download PDF

43. AB0035 A physiological network of igg autoantibodies targeting g protein coupled receptors

Author

Marques, O.C., primary, Marques, A., additional, de Vito, R., additional, Giil, L.M., additional, Rademacher, J., additional, Günther, J., additional, Marschner, G., additional, Pitann, S., additional, Adler, S., additional, Dragun, D., additional, Lamprecht, P., additional, Müller, A., additional, Yu, X., additional, Petersen, F., additional, Heidecke, H., additional, Engelhardt, B.E., additional, and Riemekasten, G., additional

Published
2018
Full Text
View/download PDF

44. The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology

Author

Loupy, A., Haas, M., Solez, K., Racusen, L., Glotz, D., Seron, D., Nankivell, B. J., Colvin, R. B., Afrouzian, M., Akalin, E., Alachkar, N., Bagnasco, S., Becker, J. U., Cornell, L., Drachenberg, C., Dragun, D., de Kort, H., Gibson, I. W., Kraus, E. S., Lefaucheur, C., Legendre, C., Liapis, H., Muthukumar, T., Nickeleit, V., Orandi, B., Park, W., Rabant, M., Randhawa, P., Reed, E. F., Roufosse, C., Seshan, S. V., Sis, B., Singh, H. K., Schinstock, C., Tambur, A., Zeevi, A., Mengel, M., Loupy, A., Haas, M., Solez, K., Racusen, L., Glotz, D., Seron, D., Nankivell, B. J., Colvin, R. B., Afrouzian, M., Akalin, E., Alachkar, N., Bagnasco, S., Becker, J. U., Cornell, L., Drachenberg, C., Dragun, D., de Kort, H., Gibson, I. W., Kraus, E. S., Lefaucheur, C., Legendre, C., Liapis, H., Muthukumar, T., Nickeleit, V., Orandi, B., Park, W., Rabant, M., Randhawa, P., Reed, E. F., Roufosse, C., Seshan, S. V., Sis, B., Singh, H. K., Schinstock, C., Tambur, A., Zeevi, A., and Mengel, M.

Abstract

The XIII Banff meeting, held in conjunction the Canadian Society of Transplantation in Vancouver, Canada, reviewed the clinical impact of updates of C4d-negative antibody-mediated rejection (ABMR) from the 2013 meeting, reports from active Banff Working Groups, the relationships of donor-specific antibody tests (anti-HLA and non-HLA) with transplant histopathology, and questions of molecular transplant diagnostics. The use of transcriptome gene sets, their resultant diagnostic classifiers, or common key genes to supplement the diagnosis and classification of rejection requires further consensus agreement and validation in biopsies. Newly introduced concepts include the i-IFTA score, comprising inflammation within areas of fibrosis and atrophy and acceptance of transplant arteriolopathy within the descriptions of chronic active T cell-mediated rejection (TCMR) or chronic ABMR. The pattern of mixed TCMR and ABMR was increasingly recognized. This report also includes improved definitions of TCMR and ABMR in pancreas transplants with specification of vascular lesions and prospects for defining a vascularized composite allograft rejection classification. The goal of the Banff process is ongoing integration of advances in histologic, serologic, and molecular diagnostic techniques to produce a consensus-based reporting system that offers precise composite scores, accurate routine diagnostics, and applicability to next-generation clinical trials. In this article, the Banff consortium presents the most updated version of the kidney, pancreas, and VCA transplant rejection classification and prospects for implementing intragraft molecular assessment. See the companion report on page 42.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results